Literature DB >> 16533729

Compassionate use of intrathecal depot liposomal cytarabine as treatment of central nervous system involvement in acute leukemia: report of 6 cases.

Juan-Manuel Sancho1, Josep-Maria Ribera, Maria-José Romero, Victoria Martín-Reina, Pilar Giraldo, Elena Ruiz.   

Abstract

The depot formulation of liposomal cytarabine (DepoCyte) has proven to be useful as intrathecal (IT) treatment of neoplastic and lymphomatous meningitis. We report the results of compassionate use of DepoCyte in 6 patients diagnosed with acute leukemia (AL) and CNS involvement. Two patients had CNS involvement at diagnosis and the remaining 4 had CNS relapse. Three patients received DepoCyte as adjuvant therapy and achieved complete response whereas 2 out of the remaining 3 cases treated with DepoCyte as the only drug showed sustained response. The side effects were mild and manageable in all patients. These findings justify the development of clinical trials to evaluate the efficacy and safety of IT depot cytarabine in meningeal involvement of AL.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16533729

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  9 in total

Review 1.  Targeting the neurovascular unit for treatment of neurological disorders.

Authors:  Reyna L Vangilder; Charles L Rosen; Taura L Barr; Jason D Huber
Journal:  Pharmacol Ther       Date:  2010-12-21       Impact factor: 12.310

2.  Results of compassionate therapy with intrathecal depot liposomal cytarabine in acute myeloid leukemia meningeosis.

Authors:  Juan-Manuel Sancho; Guillermo Deben; Anne Parker; José-Luis Piñana; Simon Bolam; Eva Sánchez-García; Eugenio Giménez; Teresa Pascual; Pascual Fernández-Abellán; Luis Palomera; Josep-Maria Ribera
Journal:  Int J Hematol       Date:  2007-07       Impact factor: 2.490

3.  Liposomal cytarabine is effective and tolerable in the treatment of central nervous system relapse of acute lymphoblastic leukemia and very aggressive lymphoma.

Authors:  Nicola Gökbuget; Christina-Maria Hartog; Renato Bassan; Heinz-Gerd Derigs; Herve Dombret; Richard Greil; Jesus-Maria Hernández-Rivas; Francoise Huguet; Tamara Intermesoli; Eric Jourdan; Christian Junghanss; Lothar Leimer; Maria-Jose Moreno; Albrecht Reichle; Josep Ribera; Matthias Schmid; Hubert Serve; Matthias Stelljes; Reingard Stuhlmann; Dieter Hoelzer
Journal:  Haematologica       Date:  2010-10-15       Impact factor: 9.941

Review 4.  Intrathecal liposomal cytarabine: more friend than foe?

Authors:  Deepa Bhojwani; Ching-Hon Pui
Journal:  Leuk Lymphoma       Date:  2008-08

5.  Intrathecal liposomal cytarabine in children under 4 years with malignant brain tumors.

Authors:  Alvaro Lassaletta; Blanca Lopez-Ibor; Elena Mateos; Marta Gonzalez-Vicent; Antonio Perez-Martinez; Julian Sevilla; Miguel A Diaz; Luis Madero
Journal:  J Neurooncol       Date:  2009-04-18       Impact factor: 4.130

6.  Successful treatment of intracranial ependymoma with leptomeningeal spread with systemic chemotherapy and intrathecal liposomal cytarabine in a two-year-old child.

Authors:  Alvaro Lassaletta; Pilar Perez-Olleros; Cristina Scaglione; Sara Sirvent; Inma De Prada; Antonio Perez-Martinez; Alberto Ruiz-Hernandez; Luis Madero
Journal:  J Neurooncol       Date:  2007-01-24       Impact factor: 4.506

7.  Novel Brentuximab Vedotin Combination Therapies Show Promising Activity in Highly Refractory CD30+ Non-Hodgkin Lymphoma: A Case Series and Review of the Literature.

Authors:  Wilfred Delacruz; Robert Setlik; Arash Hassantoufighi; Shyam Daya; Susannah Cooper; Dale Selby; Alexander Brown
Journal:  Case Rep Oncol Med       Date:  2016-10-11

Review 8.  Treatment of lymphomatous and leukemic meningitis with liposomal encapsulated cytarabine.

Authors:  Melanie Kripp; Ralf-Dieter Hofheinz
Journal:  Int J Nanomedicine       Date:  2008

Review 9.  Computational and Pharmacological Target of Neurovascular Unit for Drug Design and Delivery.

Authors:  Md Mirazul Islam; Zahurin Mohamed
Journal:  Biomed Res Int       Date:  2015-10-22       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.